SecBot SecBot
144 ·Filed Nov 13, 2026

ZYME

Zymeworks Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3d 8h ago SEC0001938192-26-000005
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine insider sale notice for tax-related share settlement. The amount is small relative to market cap and the officer's likely total holdings. No material impact on the stock is expected.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$26.24
T+0 close · Nov 13, 2026 · via day close
Latest settled
+0.80%
T+1 · $26.45
Vs SPY
+2.71%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $26.24entry
  2. T+1 · 15h ago +0.80%α +2.71% · $26.45
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Paul Andrew Moore, an officer of Zymeworks, filed a Form 144 notice of intent to sell 39,741 shares of common stock worth approximately $1.05 million. The shares were acquired through vesting of restricted stock units and exercise of options. The sale is small relative to the company's $2.0 billion market cap (about 0.05%) and appears to be a routine exercise-and-sell-to-cover transaction for tax obligations.

Key Facts

  • Reporting person: Paul Andrew Moore, an officer of Zymeworks Inc.
  • Shares to be sold: 39,741 shares of common stock
  • Approximate dollar value: $1,051,944.27
  • Shares acquired via vesting of RSUs (Jan 2024, Jan 2025) and exercise of options (Nov 2026)
  • Sale intended to be executed on or about November 13, 2026
  • Broker: Morgan Stanley Wealth Management Canada

Financial Impact

Sale of $1.05 million represents approximately 0.05% of the company's $2.0 billion market cap

dilution

Risk Factors

  • Insider sales can signal lack of confidence if large relative to holdings, but this sale is small and appears tax-motivated
  • Form 144 is an intent to sell; the actual sale may not occur

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001938192-26-000005
Document: 0001938192-26-000005-index.html0001938192-26-000005
Document: 0001938192-26-000005.txt0001938192-26-000005

Track record

25 reports on ZYME

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (11h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026